Driven by Innovation & Growth

Our mission is to promote innovation and growth through strengthened networks; advocacy; capital investment; talent attraction, development and retention; and advancing the next generation of leaders.

About Us

Virginia's Life Science Community By the Numbers

  • 3,433 Companies

    Life science companies in Virginia.

  • $8B Industry

    Life Science contributes $8B to Virginia's economy.

  • 30, 504 People

    Employed by Life Science companies in Virginia.

  • $107,281 Average Wage

    Average earnings of life science workers in Virginia.

  • 1,197 Clinical trials

    Biopharmaceutical industry-sponsored trials in Virginia per year.

News

02/09/2026

Activation Capital Expands Frontier BioHealth and Strengthens its Continuum of Support for Life Sciences Founders

Activation Capital today announced enhancements to Frontier BioHealth, building on the program’s successful 2024 launch and inaugural cohort while reinforcing its broader continuum of life sciences entrepreneurship programs designed to help science-driven companies progress toward commercialization and investor readiness. Frontier BioHealth was created to address a critical gap facing emerging biohealth founders: access to practical

02/04/2026

Governor Spanberger Announces Expansion of Paid Internship Opportunities with Virginia Businesses

Governor Abigail Spanberger today launched InternshipsVA, a new statewide program to help Virginia employers design and launch high-quality, paid internships for higher education students in Virginia. The Commonwealth has committed $14.5 million each year to support this program. The Governor was joined by leaders of the Virginia Chamber of Commerce, the Virginia Economic Development Partnership

02/03/2026

SSI Diagnostica Group Acquires InDevR

SSI Diagnostica Group, a global company specializing in testing solutions for infectious diseases, has announced the acquisition of InDevR, a Colorado-based provider of advanced multiplexed solutions for vaccine testing and quality control. The addition strengthens SSID Group’s leadership in pneumococcal vaccine QC testing with next-generation multiplexing assays and enhanced customization capabilities. InDevR will advance the Group’s offering by